The FDA database lists a supplement dated 15 October to an abbreviated new drug application for generic lamotrigine held by Impax Laboratories. The record gives no detail of what changed. Supplements to generic applications usually concern manufacturing, labelling alignment or packaging.
This is administrative. It does not signal a new indication or a safety finding, and lamotrigine's existing warnings — including serious rash with rapid titration — are unchanged.
- No change to lamotrigine indications, dosing or warnings follows from this record.
- Generic supplements usually concern manufacturing or labelling, not safety.
- Keep patients on a consistent lamotrigine product where possible, as switching can unsettle some.
- Existing advice on slow titration and rash still applies.
Why it matters
Not every regulatory listing is clinical news; this one is not.
Don't overread it
A licence supplement is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free